Hepatitis B recurrence after liver transplantation: A single center experiences and review the literature

Hepatitis Monthly

Volumn 13, Issue 1, 2013, Pages

  Dehghani, Seyed Mohsen ^a,b   Taghavi, Seyed Ali Reza ^b   Geramizadeh, Bita ^a   Nikegh balian, Saman ^a   Derakhshan, Nima ^b   Malekpour, Abdorrasoul ^b   Malek Hosseini, Seyed Ali ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis B virus; Immunosuppression; Liver transplant; Recurrence

Indexed keywords

ADEFOVIR; CYCLOSPORIN; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; COUNTER IMMUNOELECTROPHORESIS; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PREDICTION; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE;

EID: 84874104182     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6609     Document Type: Article

References (49)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev.2000;64(1):51-68.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infec-tions to cirrhosis and primary liver cancer worldwide. J Hepa-tol.2006;45(4):529-38.
3. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, et al. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transpl.2007;22(suppl 8):viii37-viii46.
4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases.2005;5(9):558-67.
5. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus re-currence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepa-tol.2001;34(6):903-10.
6. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver trans-plantation. J Clin Invest.1992;89(4):1361-5.
7. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Out-come of liver transplantation for hepatitis B in the United States. Liver Transpl.2004;10(8):968-74.
8. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatol-ogy.2002;35(6):1528-35.
9. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl.2002;8(1):2-9.
10. Weinberger KM, Wiedenmann E, Bohm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Meth-ods.2000;85(1-2):75-82.
11. Wasmuth J. Hepatology. Düsseldorf: Flying Publisher; 2009.
12. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Wag-goner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut.1992;33(10):1390-6.
13. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepa-tol.1992;14(1):104-11.
14. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B vi-rus-related liver disease. Hepatology.1991;13(4):619-26.
15. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immuno-suppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology.1995;22(1):36-43.
16. Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology.1988;167(2):630-3.
17. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl.2005;11(4):402-9.
18. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation.1996;61(9):1358-64.
19. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology.1990;12(2):364-6.
20. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepati-tis B surface antigen. N Engl J Med.1993;329(25):1842-7.
21. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl.2005;11(7):716-32.
22. Wang YM, Tang YZ. Antiviral therapy for hepatitis B virus associ-ated hepatic failure. Hepatobiliary Pancreat Dis Int.2009;8(1):17-24.
23. Seehofer D, Rayes N, Neuhaus P. Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era. Expert Rev Anti Infect Ther.2003;1(2):307-18.
24. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with anti-genically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology.1998;27(1):254-63.
25. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titre predicts fail-ure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol.1999;30(4):715-21.
26. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatol-ogy.2007;45(4):1056-75.
27. Seehofer D, Rayes N, Berg T, Neuhaus R, Muller AR, Hopf U, et al. Lamivudine as first-and second-line treatment of hepatitis B in-fection after liver transplantation. Transpl Int.2000;13(4):290-6.
28. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology.1998;28(2):585-9.
29. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lami-vudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepa-tol.2003;38(6):811-7.
30. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lami-vudine therapy provides effective prophylaxis against posttrans-plantation hepatitis B. Liver Transpl.2000;6(4):429-33.
31. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immuno-globulin to prevent reinfection after orthotopic liver transplan-tation. Clin Transplant.2003;17(3):254-8.
32. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An effica-cy and cost-effectiveness analysis of combination hepatitis B im-mune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl.2000;6(6):741-8.
33. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepa-tol.2001;34(6):895-902.
34. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmach-er U, et al. Combination prophylaxis with Hepatitis B immuno-globulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivu-dine resistance. Z Gastroenterol.2002;40(9):795-9.
35. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology.2000;32(1):129-34.
36. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation.2005;80(1 Suppl):S120-4.
37. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the se-lection of a novel mutation in the HBV polymerase. Gastroenter-ology.2003;125(2):292-7.
38. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-pos-itive patients with chronic hepatitis B virus infection. Hepatol-ogy.2004;40(3):719-26.
39. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infec-tion. Gastroenterology.2002;123(6):1831-8.
40. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treat-ment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology.2002;36(2):507-8.
41. Haberal M, Dalgic A. New concepts in organ transplantation. Transplant Proc.2004;36(5):1219-24.
42. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobili-ary Pancreat Dis Int.2005;4(4):502-8.
43. Ying C, De Clercq E, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine-and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res.2000;48(2):117-24.
44. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat.1999;6(3):229-36.
45. Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The role of mycophe-nolate acid on HBV replication in vitro. Chin J Organ Trans-plant.2003;24:310-2.
46. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol.1998;13(1):14-20.
47. Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis after short-term corticoste-roid therapy in a patients with latent chronic hepatitis B. Liv-er.2000;20(5):415-20.
48. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clinics in liver disease.2003;7(3):667.
49. Tisone G, Angelico M, Di Paolo D, editors. Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids; 1999.